Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County (Q35596600)

9 August 2017

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County (English)

1 reference

inflammatory bowel diseases

9 August 2017

0 references

inflammation

0 references

author name string

T Ljung

1

1 reference

9 August 2017

P Karlén

2

1 reference

9 August 2017

D Schmidt

3

1 reference

9 August 2017

P M Hellström

4

1 reference

9 August 2017

A Lapidus

5

1 reference

9 August 2017

I Janczewska

6

1 reference

9 August 2017

U Sjöqvist

7

1 reference

9 August 2017

R Löfberg

8

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

9 August 2017

1 reference

9 August 2017

53

1 reference

9 August 2017

6

1 reference

9 August 2017

849-853

1 reference

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-alpha

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Risk of lymphoma in inflammatory bowel disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Surgery for ulcerative colitis in the era of the pouch: the St Mark's Hospital experience

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Colorectal and extracolonic malignancy in ulcerative colitis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Extracolonic malignancies in inflammatory bowel disease.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774085

Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study

26 September 2018

1 reference

12 December 2020

Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference

1 reference

12 December 2020

Crohn's disease and cancer: a population-based cohort study

1 reference

12 December 2020

Infliximab in Crohn's disease: first anniversary clinical experience

1 reference

12 December 2020

Clinical experience with infliximab therapy in 100 patients with Crohn's disease

1 reference

12 December 2020

Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients

1 reference

12 December 2020

Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats

1 reference

12 December 2020

Infliximab for refractory ulcerative colitis

1 reference

12 December 2020

Inflammatory bowel disease is not associated with an increased risk of lymphoma

1 reference

12 December 2020

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

12 December 2020

Extraintestinal cancers in inflammatory bowel disease

1 reference

12 December 2020

Lymphoma in inflammatory bowel disease

1 reference

12 December 2020

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

1 reference

12 December 2020

Identifiers

DOI

10.1136/GUT.2003.018515

1 reference

9 August 2017

1 reference

9 August 2017

1 reference